Association holds after adjustment for unmeasured genetic, environmental factors
Diethylstilbestrol exposure during pregnancy is associated with multigenerational neurodevelopmental deficits in childhood, including ADHD.
Co-occurrence of attention-deficit/hyperactivity disorder is common in children with autism spectrum disorder.
A study of an investigational digital medicine achieves its primary efficacy end point in pediatric ADHD.
Omega-3 supplementation in children with mood disorders is associated with decreased impairment in executive functioning.
Cerebral morphometric alterations can discriminate between children with attention-deficit/hyperactivity disorder and controls.
Women with significant attention-deficit/hyperactivity disorder do not need to stop treatment during pregnancy.
Treatment with ADHD medication during pregnancy was associated with a higher risk for neonatal morbidity, especially central nervous system-related disorders such as seizures.
A majority of study participants also reported that they frequently skip doses of ADHD medication.
There is an unmet need for better treatment to manage symptom burden among US adults with ADHD.
The FDA has approved Adzenys ER extended-release oral suspension ADHD treatment for patients 6 years and older.
There does not appear to be an association between methylphenidate hydrochloride treatment for ADHD and suicide attempts.
Sunovion has submitted a New Drug Application for dasotraline, a new treatment for ADHD.
The generic forms of Strattera are the first to be approved by the FDA for the treatment of ADHD.
Girls whose mothers consumed high amounts of licorice during pregnancy have more advanced pubertal maturation at age 12 years.
More than 6 million physician visits were made by children between 4 and 17 years of age with ADHD in 2012 to 2013.
Patients diagnosed with a prior psychiatric condition have increased odds of long-term opioid receipt than patients without these conditions.
Guidelines issued by the American Academy of Pediatrics recommend behavior therapy as the first-line therapy for preschoolers.
Children exposed to acetaminophen prenatally had an increased risk of multiple behavioral difficulties.
Antidepressant use for anxiety, panic, and ADHD has increased.
Rates of chronic conditions are on the rise in children, and children living in poverty have a higher risk of ADHD and asthma, compared with wealthier children.
The rate of misuse of prescription stimulants has risen among young adults despite the rate of prescriptions remaining the same.
Children in foster care are more likely to be diagnosed with ADHD and are more likely to have a comorbid disorder.
The earlier in a pregnancy a child is born, the greater their risk for developing ADHD.
Prescription diet pills were the most popular stimulant drug misused by females, while Adderall was the drug misused most often by males.
The number of children diagnosed with attention-deficit/hyperactivity disorder was lowest among those without health insurance.
Of the patients with current ADHD, 74.0% received treatment in the past week and 44.0% had received behavioral therapy in the past year.
After one year, the children as a whole showed improvements in hyperactivity, impulsivity, inattention, and social skills.
Patients taking Vyvanse experienced a decrease in the number of binge eating days per week.
Maternal and paternal smoking during pregnancy was associated with higher ADHD risk, but the association was stronger for females.